NCT01633723View on ClinicalTrials.gov

Phase I Clinical Trial of DA-6886 in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

105

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions

Irritable Bowel Syndrome

Interventions

DRUG

DA-6886

"single dose study : DA-6886 1mg,2.5mg,5mg,10mg,20mg dosage (Dose-escalation)~multiple dose study : DA-6886 2.5mg,5mg,10mg or 5mg,10mg,20mg dosage (Dose-escalation)"

DRUG

Placebo of DA-6886

DA-6886 placebo

Trial Locations (1)

138-736

ASAN medical center, Seoul

All Listed Sponsors

lead

Dong-A ST Co., Ltd.

INDUSTRY

NCT01633723 - Phase I Clinical Trial of DA-6886 in Healthy Male Subjects | Biotech Hunter | Biotech Hunter